Crosstalk Between MAPK and PI3K/AKT Signaling Pathways in Cellular Responses: Implications for Cancer Therapy

Aditi Roy

doi:10.36676/urr.v11.i4.1304

Authors

Aditi Roy aditir339@gmail.com

DOI:

https://doi.org/10.36676/urr.v11.i4.1304

Keywords:

MAPK, PI3K/AKT, Signaling Pathways, Cellular Responses, Cancer

Abstract

This research paper aims to explore the intricate crosstalk between the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathways. These pathways play crucial roles in regulating cellular processes such as growth, proliferation, survival, and apoptosis. Dysregulation of these pathways is commonly associated with the development and progression of various cancers. By understanding the mechanisms of crosstalk between MAPK and PI3K/AKT pathways, this study seeks to identify potential therapeutic targets and strategies for more effective cancer treatment.

References

Arbabi, F., Liang, Y., & Chakrabarti, R. (2018). Crosstalk between the PI3K/AKT/mTOR and MAPK/ERK pathways in neuroblastoma. Cellular Signalling, 48, 1-9. https://doi.org/10.1016/j.cellsig.2018.04.007

Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014). KRAS: feeding pancreatic cancer proliferation. Trends in Biochemical Sciences, 39(2), 91-100. https://doi.org/10.1016/j.tibs.2013.12.004

Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017). The PI3K pathway in human disease. Cell, 170(4), 605-635. https://doi.org/10.1016/j.cell.2017.07.029

Huang, S., & Houghton, P. J. (2003). Targeting mTOR signaling for cancer therapy. Current Opinion in Pharmacology, 3(4), 371-377. https://doi.org/10.1016/S1471-4892(03)00082-0

Mendoza, M. C., Er, E. E., & Blenis, J. (2011). The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends in Biochemical Sciences, 36(6), 320-328. https://doi.org/10.1016/j.tibs.2011.03.006

Samatar, A. A., & Poulikakos, P. I. (2014). Targeting RAS-ERK signalling in cancer: promises and challenges. Nature Reviews Drug Discovery, 13(12), 928-942. https://doi.org/10.1038/nrd4281

Shafi, G., Vasu, D. R., Nair, R., & Paulose, C. S. (2010). Crosstalk between the MAPK and PI3K pathways in glioblastoma cells. Journal of Receptor and Signal Transduction Research, 30(6), 411-416. https://doi.org/10.3109/10799893.2010.518249

Vanhaesebroeck, B., Stephens, L., & Hawkins, P. (2012). PI3K signalling: the path to discovery and understanding. Nature Reviews Molecular Cell Biology, 13(3), 195-203. https://doi.org/10.1038/nrm3290

Vivanco, I., & Sawyers, C. L. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews Cancer, 2(7), 489-501. https://doi.org/10.1038/nrc839

Yuan, T. L., & Cantley, L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene, 27(41), 5497-5510. https://doi.org/10.1038/onc.2008.245

Davies, H., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949-954. https://doi.org/10.1038/nature00766

Fang, Y., & Richardson, B. C. (2005). The MAPK signalling pathways and colorectal cancer. The Lancet Oncology, 6(5), 322-327. https://doi.org/10.1016/S1470-2045(05)70168-6

Fukuda, M., Gotoh, I., Gotoh, Y., & Nishida, E. (1997). Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. The Journal of Biological Chemistry, 272(51), 32642-32648. https://doi.org/10.1074/jbc.272.51.32642

Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Reviews Drug Discovery, 4(12), 988-1004. https://doi.org/10.1038/nrd1902

Manning, B. D., & Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. Cell, 129(7), 1261-1274. https://doi.org/10.1016/j.cell.2007.06.009

McCubrey, J. A., et al. (2006). Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1773(8), 1263-1284. https://doi.org/10.1016/j.bbamcr.2006.10.001

Pearson, G., Robinson, F., Beers Gibson, T., Xu, B. E., Karandikar, M., Berman, K., & Cobb, M. H. (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrine Reviews, 22(2), 153-183. https://doi.org/10.1210/edrv.22.2.0428

Reya, T., & Clevers, H. (2005). Wnt signalling in stem cells and cancer. Nature, 434(7035), 843-850. https://doi.org/10.1038/nature03319

Sebolt-Leopold, J. S., & Herrera, R. (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Reviews Cancer, 4(12), 937-947. https://doi.org/10.1038/nrc1503

Shapiro, P. (2002). Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy. Critical Reviews in Clinical Laboratory Sciences, 39(4-5), 285-330. https://doi.org/10.1080/10408360290795502

Vivanco, I., & Sawyers, C. L. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews Cancer, 2(7), 489-501. https://doi.org/10.1038/nrc839

Zhao, J. J., & Vogt, P. K. (2008). Class I PI3K in oncogenic cellular transformation. Oncogene, 27(41), 5486-5496. https://doi.org/10.1038/onc.2008.244